G1 Therapeutics (NASDAQ:GTHX) will announce its earnings results after the market closes on Wednesday, February 21st. Analysts expect the company to announce earnings of ($0.58) per share for the quarter.

Shares of G1 Therapeutics (NASDAQ GTHX) opened at $19.69 on Tuesday. G1 Therapeutics has a twelve month low of $12.04 and a twelve month high of $28.67. The firm has a market capitalization of $558.12 and a price-to-earnings ratio of -9.16.

In other G1 Therapeutics news, major shareholder Medimmune Ventures, Inc. sold 200,000 shares of the stock in a transaction on Friday, December 15th. The stock was sold at an average price of $19.75, for a total value of $3,950,000.00. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Rajesh Malik sold 3,776 shares of the stock in a transaction on Thursday, February 15th. The stock was sold at an average price of $20.00, for a total value of $75,520.00. The disclosure for this sale can be found here. In the last quarter, insiders sold 350,458 shares of company stock worth $6,939,148.

A hedge fund recently bought a new stake in G1 Therapeutics stock. Vanguard Group Inc. purchased a new position in shares of G1 Therapeutics Inc (NASDAQ:GTHX) during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 74,000 shares of the company’s stock, valued at approximately $1,291,000. Vanguard Group Inc. owned approximately 5.00% of G1 Therapeutics at the end of the most recent quarter. 52.01% of the stock is owned by institutional investors.

Several analysts recently weighed in on GTHX shares. Cowen restated a “buy” rating on shares of G1 Therapeutics in a report on Wednesday, November 8th. BidaskClub upgraded G1 Therapeutics from a “sell” rating to a “hold” rating in a report on Wednesday, January 3rd. Zacks Investment Research lowered G1 Therapeutics from a “hold” rating to a “sell” rating in a report on Thursday, February 8th. JPMorgan Chase & Co. increased their price target on G1 Therapeutics to $30.00 in a report on Monday, February 5th. Finally, BTIG Research started coverage on G1 Therapeutics in a report on Tuesday, December 19th. They set a “buy” rating and a $38.00 price target on the stock. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and five have assigned a buy rating to the company. The stock has an average rating of “Buy” and a consensus target price of $32.80.

ILLEGAL ACTIVITY NOTICE: This piece was originally posted by Watch List News and is owned by of Watch List News. If you are reading this piece on another publication, it was copied illegally and republished in violation of US & international copyright and trademark laws. The legal version of this piece can be read at https://www.watchlistnews.com/g1-therapeutics-gthx-set-to-announce-earnings-on-wednesday/1877688.html.

About G1 Therapeutics

G1 Therapeutics, Inc is a United States-based clinical-stage biopharmaceutical company. The Company is engaged in developing small-molecule therapies for the treatment of cancer. Its two clinical-stage candidates are trilaciclib (G1T28) and G1T38, which are potent, selective inhibitors of the validated kinase targets CDK4/6.

Receive News & Ratings for G1 Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for G1 Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.